CompletedEUCTR 2005-005054-46
An International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-controlled Study of the Efficacy and Safety of Sustained-release Quetiapine Fumarate (Seroquel SR...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesAnxiety
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Czechia · Denmark and 5 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 805
- Sponsor
- AstraZeneca AB
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Czechia, Denmark, Finland, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2005-005054-46
- Official title
Show the full official title
An International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-controlled Study of the Efficacy and Safety of Sustained-release Quetiapine Fumarate (Seroquel SR...
Get this study by email
Recruitment & locations
CompletedCzechia · Denmark · Finland
4 more locations
- Germany
- Slovakia
- Spain
- Sweden
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca AB.
Want to explore more studies?
Explore studiesRelated studies
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
A double-blind, randomised, placebo-controlled, multicentre, relapse-prevention study with Lu AA21004 in patients with Generalised Anxiety Disorder (GAD)